Skip to content Skip to footer
Viewpoints_Dr. Gail McIntyre

PharmaShots Interview: Aravive’ s Dr. Gail McIntyre Shares Insight on AVB-500 and its Potential Against ccRCC

In an interview with PharmaShots, Dr. Gail McIntyre, CEO of Aravive shared her views on the AVB-500, its potential against ccRCC, and the design of the clinical trial evaluating the therapy. He also shed light on epidemiology of Clear Cell Renal Cell Carcinoma.Shots:AVB-500 is being evaluated in ccRCC, has been tested in preclinical models of…

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]